News | Radiation Therapy | September 24, 2019

Hippocampal Avoidance Using IMRT Now Recommended as Standard of Care for Brain Metastases

Patients benefit from preserved cognitive function, fewer neurological symptoms

Hippocampal Avoidance Using IMRT Now Recommended as Standard of Care for Brain Metastases

September 24, 2019 — Patients with brain metastases who received whole-brain radiotherapy that avoided memory-specific hippocampal neural stem cells experienced preserved cognitive function, according to results from an NRG Oncology clinical trial. Those patients also reported fewer neurologic symptoms and better cognition over time. The results were presented at the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 15-18 in Chicago.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center and co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center Warrenville (Ill.), presented updated results of the phase III trial. Gondi was lead author and co-principal investigator of the trial. Paul D. Brown, M.D., of the Mayo Clinic (Rochester, Minn.) was also co-principal investigator of the trial.

“We hypothesized that by using advanced radiotherapy techniques to spare the hippocampal neural stem cell compartment from significant doses of radiation, we may be able to prevent radiotherapy-related adverse cognitive effects,” Gondi said. “Now with longer-term follow-up, results confirm that hippocampal avoidance using intensity modulated radiation therapy should be considered the standard of care for patients with brain metastases who are eligible to receive whole-brain radiotherapy.”

To study the hypothesis that radiation to the hippocampal stem cells plays a role in cognitive decline, 518 patients were randomized to whole brain radiotherapy plus memantine with or without hippocampal avoidance. The results of the clinical trial found a 26 percent relative reduction in risk of cognitive toxicity following whole brain radiation therapy with hippocampal avoidance versus whole-brain radiotherapy. The cognitive function benefit of hippocampal avoidance did not differ by age.

Over time, patients who received treatment that avoided the hippocampus continued to maintain measurable improvements in cognition. They self-reported fewer neurologic symptoms, less interference of neurologic symptoms with their daily activities and fewer problems remembering things in their daily lives. These patients experienced toxicity, intracranial progression-free survival and overall survival outcomes similar to those experienced by patients who had whole-brain radiotherapy.

“These results revolutionize our understanding of the cognitive effects of brain irradiation in a manner that has far-reaching implications in terms of the safer radiotherapy treatment of primary or metastatic brain tumors,” Gondi said. “Our phase III trial not only provides evidence for practice change in the management of brain metastases, but also builds upon decades of preclinical and clinical research to definitely establish the hippocampus as a radiosensitive and cognition-specific organ at risk during brain irradiation.”

Watch the VIDEO: Preserving Neurocognitive Function During Whole-Brain Radiotherapy, an interview with Gondi about the trial at ASTRO 2019.

For more information: www.astro.org

Related Content

Additional coverage from ASTRO 2019

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
An image on Brigham and Women's Hospital's 7T MRI system

An image on Brigham and Women's Hospital's 7T MRI system. Image courtesy of Brigham and Women's Hospital

News | Magnetic Resonance Imaging (MRI) | November 13, 2019
November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may b
Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

News | SPECT Imaging | November 08, 2019
November 8, 2019 — Using ground-breaking technology, researchers at the...
This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

News | Clinical Trials | November 08, 2019
November 8, 2019 — As the outbreak of lung injuries and deaths associated with e-cigarettes, or...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
The Neuroreader software program quantifies brain volume in study participants with TBI

The Neuroreader software program quantifies brain volume in study participants with TBI. Image courtesy of UCLA Health.

News | Clinical Trials | October 29, 2019
October 29, 2019 — A UCLA-led...